search
Back to results

Transfer of Healthy Gut Flora for Restoration of Intestinal Microbiota Via Enema for Patients in the Rehabilitative Phase of Malnutrition (THRIVE)

Primary Purpose

Severe Acute Malnutrition, Moderate Acute Malnutrition

Status
Terminated
Phase
Phase 1
Locations
South Africa
Study Type
Interventional
Intervention
Fecal Microbiota Transplantation
Sponsored by
Microbiome Health Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Severe Acute Malnutrition focused on measuring SAM, MAM

Eligibility Criteria

12 Months - 60 Months (Child)All SexesDoes not accept healthy volunteers

Participant Inclusion Criteria

Participants eligible to participate in this study must meet the following inclusion criteria:

  1. Age 12 to 60 months.
  2. Current diagnosis of malnutrition (defined as a WHZ less than -2 according to the WHO 2006 standards or a MUAC less than 125mm) with failure to respond nutritionally, defined as:

    a. A WHZ of less than -2 according or a mid-upper-arm circumference of less than 125 mm i. No medical complications present ii. Participant is sufficiently alert and successfully passes the appetite test which involves consumption of breastmilk or a ready to use therapeutic food (RUTF) under supervision.

    iii. Participant is in the rehabilitation phase of treatment for malnutrition

  3. HIV negative
  4. Received at last four weeks of optimal WHO treatment for malnutrition:

    1. Micronutrient supplementation (Vitamin A, zinc and iron) as recommended by local guidelines
    2. Nutritional rehabilitation as recommended by local guidelines.
  5. Written informed consent obtained by parent or caregiver.

Participant Exclusion Criteria

Participants will not be able to participate if they meet any of the following exclusion criteria:

  1. Evidence of current complicated malnutrition defined as any of the following:

    1. Admitted to acute care ward as inpatient
    2. Signs of severe acute infection such as pneumonia, bacteremia, meningitis. Minor infections such as candida dermatitis, pharyngitis, upper respiratory tract infections will be eligible for inclusion at the discretion of the study physician.
    3. One or more WHO Integrated Management of Childhood Illness danger signs.(3)
    4. Failure to pass appetite test.
    5. Presence of known comorbid diseases such as pulmonary Tuberculosis on treatment, cystic fibrosis, type I diabetes mellitus, intestinal malabsorptive syndromes, chronic lung disease, chronic liver disease, chronic renal disease, chronic neurological diseases (e.g. cerebral palsy) or malignancy undergoing active chemotherapy.
    6. Bilateral pitting pedal edema or generalized anasarca
  2. Have taken antibiotics in the past seven days before the Day 0 visit or are anticipated to need antibiotics up to seven days before the Day 0 visit.
  3. Congenital malformations, syndromic conditions, and congenital metabolic abnormalities (inborn errors of metabolism) that may adversely affect growth and in the view of the clinician, exposes the child to increased risk.

    a. Fetal alcohol syndrome (FAS) is not an exclusion.

  4. Presence of bilateral pitting edema Grade 2.
  5. Contraindications to rectal catheter enema:

    1. Anorectal malformations
    2. Rectal prolapse
    3. Hirschsprungs disease
    4. Other contraindication to enema.
  6. Primary immune deficiencies
  7. Acute, persistent or chronic diarrhea.
  8. Dysentery
  9. Intestinal abnormalities including malformations, Hirschsprungs disease and short bowel syndrome
  10. Any condition that the physician investigators deems unsafe, including other conditions or medications that the investigator determines puts the participant at greater risk from MTT

Sites / Locations

  • University of Cape Town

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Fecal Microbiota Transplant

Standard of Care

Arm Description

FMT by enema: 10mL/kg (maximum 150mL) of healthy donor human intestinal microbiota will be infused.

Standard of care treatment for malnutrition as prescribed by local and national Department of Health Guidelines

Outcomes

Primary Outcome Measures

Serious Adverse Events
Number of participants with an Adverse Event grade 2 or above up to 56 days post-treatment

Secondary Outcome Measures

Nutritional recovery:
Proportion of participants with nutritional recovery at day 56 after randomization. Defined as weight for height z-score (WHZ) ≥ -2 or MUAC ≥ 125 mm. In cases where there is a significant discrepancy between the weight and MUAC the participants weight will be used as the definitive measure.
Clinical:
Presence of signs and symptoms or complications of acute malnutrition. Clinical signs include fever (axillary temperature > 38.5⁰C), tachypnea (average of two measures; defined as respiratory rate of > 40 breaths per minute for children 12-60 months of age). Symptoms include diarrhea (≥ 3 loose stools in the last 24 hours), vomiting, and cough.
Microbiological:
Assess engraftment of donor microbial communities in recipients through taxonomic characterization of donor and recipient microbiota pre- and post-MTT using both 16S rRNA and metagenomic techniques.
Translational:
Assess the capacity for MTT to normalize biomarkers correlated with disease status and mortality in malnutrition. Stool biomarkers include Myeloperoxidase, Alpha-1-Antitrypsin, fecal calprotectin and neopterin. Serological biomarkers include CRP, endotoxin assay (Hek-Blue), and leptin.

Full Information

First Posted
December 12, 2016
Last Updated
January 11, 2021
Sponsor
Microbiome Health Research Institute
Collaborators
University of Cape Town
search

1. Study Identification

Unique Protocol Identification Number
NCT03087097
Brief Title
Transfer of Healthy Gut Flora for Restoration of Intestinal Microbiota Via Enema for Patients in the Rehabilitative Phase of Malnutrition
Acronym
THRIVE
Official Title
Transfer of Healthy Gut Flora for Restoration of Intestinal Microbiota Via Enema (THRIVE) for Patients in the Rehabilitative Phase of Malnutrition: A Pilot Study Evaluating Microbial Engraftment, Safety and Nutritional Outcomes
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Terminated
Why Stopped
COVID-19 pandemic and resource constraints
Study Start Date
April 11, 2019 (Actual)
Primary Completion Date
July 21, 2020 (Actual)
Study Completion Date
July 21, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Microbiome Health Research Institute
Collaborators
University of Cape Town

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This single-center, randomized, open-label trial will compare the safety of MTT delivered by rectal catheter enema in participants 12-60 months of age with malnutrition (moderate acute malnutrition [MAM] or severe acute malnutrition [SAM]) who are in the rehabilitative phase of treatment and have failed to respond to at least 4 weeks of standard therapy. Participants must meet inclusion criteria, no exclusion criteria prior to randomization. Participants will then be randomized in a 1:1 ratio at each site to 1 of 2 treatment groups: MTT by rectal catheter enema: 10mL/kg (maximum 150mL, +/- 5ml) of healthy donor human intestinal microbiota will be infused. Standard of care treatment for malnutrition as prescribed by local and national Department of Health Guidelines Participants will be evaluated through 56 days (±3) after randomization for primary outcomes (safety) as well as secondary outcomes (nutritional, clinical and microbiological response). Participant blood and urine samples will be collected at enrollment and day 56. Participant stool samples will be collected at enrollment and through days 3, 7, 21 and 56, thereafter, 3 months, 4 months, and 6 months. A caregiver stool sample will be collected at enrollment and day 56. Samples will be used for microbiome determination and other exploratory microbiological endpoints. An aliquot of donor stool will also be stored for microbiome determination and other exploratory microbiological endpoints and assessment of newly acquired infectious agents.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Severe Acute Malnutrition, Moderate Acute Malnutrition
Keywords
SAM, MAM

7. Study Design

Primary Purpose
Other
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
5 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Fecal Microbiota Transplant
Arm Type
Experimental
Arm Description
FMT by enema: 10mL/kg (maximum 150mL) of healthy donor human intestinal microbiota will be infused.
Arm Title
Standard of Care
Arm Type
No Intervention
Arm Description
Standard of care treatment for malnutrition as prescribed by local and national Department of Health Guidelines
Intervention Type
Biological
Intervention Name(s)
Fecal Microbiota Transplantation
Other Intervention Name(s)
Microbiota transfer therapy (MTT)
Intervention Description
Fecal microbiota delivered by rectal catheter enema in participants 12-60 months of age with malnutrition (MAM or SAM) who are in the rehabilitation phase of treatment and have failed to respond to at least 4 weeks of standard therapy.
Primary Outcome Measure Information:
Title
Serious Adverse Events
Description
Number of participants with an Adverse Event grade 2 or above up to 56 days post-treatment
Time Frame
56 days
Secondary Outcome Measure Information:
Title
Nutritional recovery:
Description
Proportion of participants with nutritional recovery at day 56 after randomization. Defined as weight for height z-score (WHZ) ≥ -2 or MUAC ≥ 125 mm. In cases where there is a significant discrepancy between the weight and MUAC the participants weight will be used as the definitive measure.
Time Frame
56 days
Title
Clinical:
Description
Presence of signs and symptoms or complications of acute malnutrition. Clinical signs include fever (axillary temperature > 38.5⁰C), tachypnea (average of two measures; defined as respiratory rate of > 40 breaths per minute for children 12-60 months of age). Symptoms include diarrhea (≥ 3 loose stools in the last 24 hours), vomiting, and cough.
Time Frame
56 days
Title
Microbiological:
Description
Assess engraftment of donor microbial communities in recipients through taxonomic characterization of donor and recipient microbiota pre- and post-MTT using both 16S rRNA and metagenomic techniques.
Time Frame
56 Days
Title
Translational:
Description
Assess the capacity for MTT to normalize biomarkers correlated with disease status and mortality in malnutrition. Stool biomarkers include Myeloperoxidase, Alpha-1-Antitrypsin, fecal calprotectin and neopterin. Serological biomarkers include CRP, endotoxin assay (Hek-Blue), and leptin.
Time Frame
56 Days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Months
Maximum Age & Unit of Time
60 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Participant Inclusion Criteria Participants eligible to participate in this study must meet the following inclusion criteria: Age 12 to 60 months. Current diagnosis of malnutrition (defined as a WHZ less than -2 according to the WHO 2006 standards or a MUAC less than 125mm) with failure to respond nutritionally, defined as: a. A WHZ of less than -2 according or a mid-upper-arm circumference of less than 125 mm i. No medical complications present ii. Participant is sufficiently alert and successfully passes the appetite test which involves consumption of breastmilk or a ready to use therapeutic food (RUTF) under supervision. iii. Participant is in the rehabilitation phase of treatment for malnutrition HIV negative Received at last four weeks of optimal WHO treatment for malnutrition: Micronutrient supplementation (Vitamin A, zinc and iron) as recommended by local guidelines Nutritional rehabilitation as recommended by local guidelines. Written informed consent obtained by parent or caregiver. Participant Exclusion Criteria Participants will not be able to participate if they meet any of the following exclusion criteria: Evidence of current complicated malnutrition defined as any of the following: Admitted to acute care ward as inpatient Signs of severe acute infection such as pneumonia, bacteremia, meningitis. Minor infections such as candida dermatitis, pharyngitis, upper respiratory tract infections will be eligible for inclusion at the discretion of the study physician. One or more WHO Integrated Management of Childhood Illness danger signs.(3) Failure to pass appetite test. Presence of known comorbid diseases such as pulmonary Tuberculosis on treatment, cystic fibrosis, type I diabetes mellitus, intestinal malabsorptive syndromes, chronic lung disease, chronic liver disease, chronic renal disease, chronic neurological diseases (e.g. cerebral palsy) or malignancy undergoing active chemotherapy. Bilateral pitting pedal edema or generalized anasarca Have taken antibiotics in the past seven days before the Day 0 visit or are anticipated to need antibiotics up to seven days before the Day 0 visit. Congenital malformations, syndromic conditions, and congenital metabolic abnormalities (inborn errors of metabolism) that may adversely affect growth and in the view of the clinician, exposes the child to increased risk. a. Fetal alcohol syndrome (FAS) is not an exclusion. Presence of bilateral pitting edema Grade 2. Contraindications to rectal catheter enema: Anorectal malformations Rectal prolapse Hirschsprungs disease Other contraindication to enema. Primary immune deficiencies Acute, persistent or chronic diarrhea. Dysentery Intestinal abnormalities including malformations, Hirschsprungs disease and short bowel syndrome Any condition that the physician investigators deems unsafe, including other conditions or medications that the investigator determines puts the participant at greater risk from MTT
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Majdi A Osman, MD MPH
Organizational Affiliation
Microbiome Health Research Institute
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Shrish Budree, MD MBChB DCH FCPeds
Organizational Affiliation
Microbiome Health Research Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Cape Town
City
Cape Town
Country
South Africa

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Transfer of Healthy Gut Flora for Restoration of Intestinal Microbiota Via Enema for Patients in the Rehabilitative Phase of Malnutrition

We'll reach out to this number within 24 hrs